Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

Overview

Journal Cancer Res

Specialty Oncology

Date 2010 Jul 16

PMID 20631075

Citations 348

Authors

Rajeev K Shrimali

Zhiya Yu

Marc R Theoret

Dhanalakshmi Chinnasamy

Nicholas P Restifo

Steven A Rosenberg

Affiliations

Soon will be listed here.

Abstract

Adoptive cell transfer (ACT)-based immunotherapies can mediate objective cancer regression in animal models and in up to 70% of patients with metastatic melanoma; however, it remains unclear whether the tumor vasculature impedes the egress of tumor-specific T cells, thus hindering this immunotherapy. Disruption of the proangiogenic interaction of vascular endothelial growth factor (VEGF) with its receptor (VEGFR-2) has been reported to "normalize" tumor vasculature, enhancing the efficacy of chemotherapeutic agents by increasing their delivery to the tumor intersitium. We thus sought to determine whether disrupting VEGF/VEGFR-2 signaling could enhance the effectiveness of ACT in a murine cancer model. The administration of an antibody against mouse VEGF synergized with ACT to enhance inhibition of established, vascularized, B16 melanoma (P = 0.009) and improve survival (P = 0.003). Additive effects of an antibody against VEGFR-2 in conjunction with ACT were seen in this model (P = 0.013). Anti-VEGF, but not anti-VEGFR-2, antibody significantly increased infiltration of transferred cells into the tumor. Thus, normalization of tumor vasculature through disruption of the VEGF/VEGFR-2 axis can increase extravasation of adoptively transferred T cells into the tumor and improve ACT-based immunotherapy. These studies provide a rationale for the exploration of combining antiangiogenic agents with ACT for the treatment of patients with cancer.

Citing Articles

Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies.

Sherpally D, Manne A Cancers (Basel). 2025; 17(4).

PMID: 40002184 PMC: 11853216. DOI: 10.3390/cancers17040589.

A stumbling block in pancreatic cancer treatment: drug resistance signaling networks.

Liu J, Zhang B, Huang B, Zhang K, Guo F, Wang Z Front Cell Dev Biol. 2025; 12:1462808.

PMID: 39872846 PMC: 11770040. DOI: 10.3389/fcell.2024.1462808.

Evaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer.

Abdallah M, Voland R, Decamp M, Flickinger J, Pacioles T, Jamil M Cancers (Basel). 2025; 16(24.

PMID: 39766108 PMC: 11674749. DOI: 10.3390/cancers16244207.

Hybrid model of tumor growth, angiogenesis and immune response yields strategies to improve antiangiogenic therapy.

Hadjigeorgiou A, Stylianopoulos T Unknown. 2025; 1(1):4.

PMID: 39759959 PMC: 11698377. DOI: 10.1038/s44341-024-00002-2.

Revolutionizing cancer treatment: the rise of personalized immunotherapies.

Fayyaz A, Haqqi A, Khan R, Irfan M, Khan K, Reiner Z Discov Oncol. 2024; 15(1):756.

PMID: 39692978 PMC: 11655907. DOI: 10.1007/s12672-024-01638-1.

References

Kim K, Li B, Winer J, Armanini M, Gillett N, PHILLIPS H . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4. DOI: 10.1038/362841a0. View

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

Li B, Lalani A, Harding T, Luan B, Koprivnikar K, Tu G . Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res. 2006; 12(22):6808-16. DOI: 10.1158/1078-0432.CCR-06-1558. View

Mulligan J, Day T, Gillespie M, Rosenzweig S, Young M . Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum Immunol. 2009; 70(6):375-82. PMC: 2746465. DOI: 10.1016/j.humimm.2009.01.014. View

Jain R, Duda D, Clark J, Loeffler J . Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006; 3(1):24-40. DOI: 10.1038/ncponc0403. View

Manning E, Ullman J, Leatherman J, Asquith J, Hansen T, Armstrong T . A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 2007; 13(13):3951-9. DOI: 10.1158/1078-0432.CCR-07-0374. View

Gerber H, Ferrara N . Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005; 65(3):671-80. View

Prewett M, Huber J, Li Y, Santiago A, OConnor W, King K . Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999; 59(20):5209-18. View

10.

Crawford Y, Ferrara N . VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 2008; 335(1):261-9. DOI: 10.1007/s00441-008-0675-8. View

11.

Tong R, Boucher Y, Kozin S, Winkler F, Hicklin D, Jain R . Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004; 64(11):3731-6. DOI: 10.1158/0008-5472.CAN-04-0074. View

12.

Folkman J . Angiogenesis. Annu Rev Med. 2006; 57:1-18. DOI: 10.1146/annurev.med.57.121304.131306. View

13.

Morgan R, Dudley M, Wunderlich J, Hughes M, Yang J, Sherry R . Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314(5796):126-9. PMC: 2267026. DOI: 10.1126/science.1129003. View

14.

Dudley M, Yang J, Sherry R, Hughes M, Royal R, Kammula U . Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008; 26(32):5233-9. PMC: 2652090. DOI: 10.1200/JCO.2008.16.5449. View

15.

Gabrilovich D, Chen H, Girgis K, Cunningham H, Meny G, Nadaf S . Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996; 2(10):1096-103. DOI: 10.1038/nm1096-1096. View

16.

Gattinoni L, Klebanoff C, Palmer D, Wrzesinski C, Kerstann K, Yu Z . Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005; 115(6):1616-26. PMC: 1137001. DOI: 10.1172/JCI24480. View

17.

Ohm J, Carbone D . VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 2001; 23(2-3):263-72. DOI: 10.1385/IR:23:2-3:263. View

18.

Rosenberg S . Overcoming obstacles to the effective immunotherapy of human cancer. Proc Natl Acad Sci U S A. 2008; 105(35):12643-4. PMC: 2529039. DOI: 10.1073/pnas.0806877105. View

19.

Ohm J, Gabrilovich D, Sempowski G, Kisseleva E, Parman K, Nadaf S . VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003; 101(12):4878-86. DOI: 10.1182/blood-2002-07-1956. View

20.

Jain R . Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307(5706):58-62. DOI: 10.1126/science.1104819. View